New antibody drug targets COVID-19 early
NCT ID NCT07156864
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug called B10-FC, made from human antibodies, to see if it is safe and how the body processes it. It involves 35 healthy adults and COVID-19 patients who receive a single dose. The goal is to find a treatment that fights the virus early in infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.